High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade
Michael K. Kießling(German Cancer Research Center), Reinhard Dummer(University of Zurich)
Cited by 77
Related Papers
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective
|Cancer Cell|2021|108
Mutant HRAS as novel target for MEK and mTOR inhibitors
|Oncotarget|2015|59